Preexisting and PostCOVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer (Rated: Objective) https://t.co/9tF08dkaQp
RT @TatjanaBilich: Very proud of our work published in @CD_AACR !!!
RT @TatjanaBilich: Very proud of our work published in @CD_AACR !!! https://t.co/JDszu3Pkq1
Very proud of our work published in @CD_AACR !!!
RT @CD_AACR: From the August issue: Pre-existing and post-#COVID19 immune responses to #SARS-CoV-2 in patients with cancer. https://t.co/Mg…
RT @CD_AACR: From the August issue: Pre-existing and post-#COVID19 immune responses to #SARS-CoV-2 in patients with cancer. https://t.co/Mg…
From the August issue: Pre-existing and post-#COVID19 immune responses to #SARS-CoV-2 in patients with cancer. https://t.co/MgP7n6CQWY @tatjanaBilich @mroerden @JulianeWalz @LabWalz @uktuebingen @CoE_iFIT @uni_tue https://t.co/QR6qQCdC4m
RT @SyedAAhmad5: Why we need to protect our cancer patients. 👇🏼👇🏼👇🏼 Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patien…
RT @SyedAAhmad5: Why we need to protect our cancer patients. 👇🏼👇🏼👇🏼 Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patien…
Why we need to protect our cancer patients. 👇🏼👇🏼👇🏼 Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer @CD_AACR @UCHealthNews @SWOG https://t.co/JGLs6EoSHX
with worsening courses of severe #COVID. https://t.co/F5n9Y2a5g2
Our latest publication in Cancer Discovery (@CD_AACR) reporting on T-cell responses to #SARSCoV2 in #cancer patients. https://t.co/hLfJwqXF2H
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
RT @Daltmann10: Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer | Cancer Discovery https://t.co/V5QTRR…
”This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer.” Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer | Cancer Discovery https://t.co/q
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
RT @Daltmann10: Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer | Cancer Discovery https://t.co/V5QTRR…
RT @Daltmann10: Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer | Cancer Discovery https://t.co/V5QTRR…
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer | Cancer Discovery https://t.co/V5QTRRNhVW
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
RT @TatjanaBilich: Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #ca…
Out now in the current issue of Cancer Discovery @CD_AACR: our @LabWalz article on T-cell responses to #SARSCoV2 in #cancer patients. https://t.co/jNCK7xZg0I RT greatly appreciated.
Link to the related article: https://t.co/CGqYIvAi89
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer https://t.co/PRzwy66aSk
RT @NatRevClinOncol: Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patien…
@Christi43738671 @quutschi Doch, z.B. Arbeiten von Fr. Dr. Walz: "...pre-existing SARS-CoV-2 cross-reactive CD4+ T cell responses..." https://t.co/NrdPZuY7ml
RT @NatRevClinOncol: Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patien…
RT @NatRevClinOncol: Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patien…
RT @NatRevClinOncol: Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patien…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
Not just a matter of serology! #COVID19
RT @NatRevClinOncol: Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patien…
Two studies indicate the importance of T cell responses to SARS-CoV-2 in determining the outcome of COVID-19 in patients with cancer: https://t.co/PvKjQurqGd & https://t.co/xrwGiG07or #COVID19
RT @DNA_RNA_Uni: @CoE_iFIT @LabWalz @AACR A nice study! 🙂 Must-read 👀 Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in canc…
RT @DNA_RNA_Uni: @CoE_iFIT @LabWalz @AACR A nice study! 🙂 Must-read 👀 Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in canc…
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients (Rated: Objective) https://t.co/MtSuc3RXNb
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients - https://t.co/DhnGPEgwme
RT @DNA_RNA_Uni: @CoE_iFIT @LabWalz @AACR A nice study! 🙂 Must-read 👀 Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in canc…
RT @DNA_RNA_Uni: @CoE_iFIT @LabWalz @AACR A nice study! 🙂 Must-read 👀 Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in canc…
@CoE_iFIT @LabWalz @AACR A nice study! 🙂 Must-read 👀 Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients https://t.co/KeGEFa6q3D 🧬👩🔬 #COVID19 #SARSCoV2 #tcell #immunity #virus #RNA #coronavirus #AcademicChatter #AcademicTwitt
RT @infdisease_news: The intensity, expandability, and diversity of SARS-CoV-2 T cell responses were profoundly reduced in #CancerPatients…
RT @infdisease_news: The intensity, expandability, and diversity of SARS-CoV-2 T cell responses were profoundly reduced in #CancerPatients…
RT @infdisease_news: The intensity, expandability, and diversity of SARS-CoV-2 T cell responses were profoundly reduced in #CancerPatients…
The intensity, expandability, and diversity of SARS-CoV-2 T cell responses were profoundly reduced in #CancerPatients compared to healthy volunteers, reports researchers from @uni_tue and @DKFZ. https://t.co/FWVRGXnMAh https://t.co/L8tN8X5nLO
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
'SARSCoV2 ab responses did not differ between COVID19 cancer patients & healthy volunteers, intensity, expandability & diversity of SARSCoV2 T cell responses were profoundly reduced in cancer patients, and the latter associated with severe COVID19'
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @AnnikaNel: Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at…
RT @AnnikaNel: Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at…
RT @ElizSMcKenna: Online now in @CD_AACR: Pre-existing and post-#COVID19 immune responses to SARS-CoV-2 in patients with cancer @tatjanaBil…
RT @ElizSMcKenna: 👇Tweetorial on today's new @CD_AACR paper! #COVID19andCancer
RT @ElizSMcKenna: Online now in @CD_AACR: Pre-existing and post-#COVID19 immune responses to SARS-CoV-2 in patients with cancer @tatjanaBil…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @AnnikaNel: Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
👇Tweetorial on today's new @CD_AACR paper! #COVID19andCancer
Online now in @CD_AACR: Pre-existing and post-#COVID19 immune responses to SARS-CoV-2 in patients with cancer @tatjanaBilich @mroerden @JulianeWalz @LabWalz @uktuebingen @CoE_iFIT @uni_tue https://t.co/qIaAFo0IZx
RT @AnnikaNel: Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @AnnikaNel: Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at…
Check out our latest work on “Pre-existing and post-COVID-19 #Immune responses to #SARSCoV2 in #Cancer patients” out now at @CD_AACR Cancer Discovery https://t.co/M74CpNO6hu
Pressemitteilung zu unserer Publikation zur Untersuchung der Immunität gegen #SARSCoV2 in Krebspatienten veröffentlicht in @CD_AACR https://t.co/05ivhMwKLP https://t.co/61uf6SsqYs
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
RT @LabWalz: 1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @C…
1/ Out now: our latest @walzlab work on “Pre-existing and post-COVID-19 immune responses to #SARS-CoV-2 in cancer patients” @CD_AACR Cancer Discovery https://t.co/05ivhMwKLP Check it out. RT very much appreciated!